Global Small Molecule Drug CDMO Services 麻豆原创 Research Report 2024

Publication ID:

PB504240143

Publication Date:

April 3, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Small molecule drug CDMO services refer to outsourcing services for the development and production of small molecule drugs. CDMO (Contract Development and Manufacturing Organization) is a third-party organization that specializes in drug development and production. It provides customized services to pharmaceutical companies, covering the entire process from the drug development stage to the commercial production stage. CDMO services for small molecule drugs usually include drug development support, clinical trial support, production process optimization, commercial production, quality control and compliance support. By choosing CDMO services, pharmaceutical companies can focus on their core business and outsource drug R&D and production to professional organizations, thereby improving efficiency, reducing risks, and accelerating the launch of new drugs.
The global Small Molecule Drug CDMO Services market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Small Molecule Drug CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Small Molecule Drug CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Small Molecule Drug CDMO Services in Clinical Treatment is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Small Molecule Drug CDMO Services include Gliead, Boehringer Ingelheim, Vertex, Mirati Therapeutics, AMPAC, Pfizer, Polypeptide, Bachem, Merck, Asymchem, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Small Molecule Drug CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Molecule Drug CDMO Services.
The Small Molecule Drug CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Small Molecule Drug CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Molecule Drug CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Thermo Fisher Scientific
Zhejiang Jiuzhou Pharmaceutical
Porton Fine Chemicals
Lonza Group
JOINN Biologics
Zhejiang Langhua Pharmaceutical
Kingchem (Liaoning) Life Science
Segment by Type
Preparation
Chemical API
Segment by Application
Clinical Treatment
Medical Research
Commercial Production
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Molecule Drug CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Small Molecule Drug CDMO Services 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Preparation
1.2.3 Chemical API
1.3 麻豆原创 by Application
1.3.1 Global Small Molecule Drug CDMO Services 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Clinical Treatment
1.3.3 Medical Research
1.3.4 Commercial Production
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Molecule Drug CDMO Services 麻豆原创 Perspective (2019-2030)
2.2 Global Small Molecule Drug CDMO Services Growth Trends by Region
2.2.1 Global Small Molecule Drug CDMO Services 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Small Molecule Drug CDMO Services Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Small Molecule Drug CDMO Services Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Small Molecule Drug CDMO Services 麻豆原创 Dynamics
2.3.1 Small Molecule Drug CDMO Services Industry Trends
2.3.2 Small Molecule Drug CDMO Services 麻豆原创 Drivers
2.3.3 Small Molecule Drug CDMO Services 麻豆原创 Challenges
2.3.4 Small Molecule Drug CDMO Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Molecule Drug CDMO Services Players by Revenue
3.1.1 Global Top Small Molecule Drug CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Small Molecule Drug CDMO Services Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Small Molecule Drug CDMO Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Small Molecule Drug CDMO Services Revenue
3.4 Global Small Molecule Drug CDMO Services 麻豆原创 Concentration Ratio
3.4.1 Global Small Molecule Drug CDMO Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Molecule Drug CDMO Services Revenue in 2023
3.5 Global Key Players of Small Molecule Drug CDMO Services Head office and Area Served
3.6 Global Key Players of Small Molecule Drug CDMO Services, Product and Application
3.7 Global Key Players of Small Molecule Drug CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Molecule Drug CDMO Services Breakdown Data by Type
4.1 Global Small Molecule Drug CDMO Services Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Small Molecule Drug CDMO Services Forecasted 麻豆原创 Size by Type (2025-2030)
5 Small Molecule Drug CDMO Services Breakdown Data by Application
5.1 Global Small Molecule Drug CDMO Services Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Small Molecule Drug CDMO Services Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Small Molecule Drug CDMO Services 麻豆原创 Size (2019-2030)
6.2 North America Small Molecule Drug CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2019-2024)
6.4 North America Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Molecule Drug CDMO Services 麻豆原创 Size (2019-2030)
7.2 Europe Small Molecule Drug CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2019-2024)
7.4 Europe Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Molecule Drug CDMO Services 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Small Molecule Drug CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Small Molecule Drug CDMO Services 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Small Molecule Drug CDMO Services 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Molecule Drug CDMO Services 麻豆原创 Size (2019-2030)
9.2 Latin America Small Molecule Drug CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Molecule Drug CDMO Services 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Small Molecule Drug CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Small Molecule Drug CDMO Services 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gliead
11.1.1 Gliead Company Details
11.1.2 Gliead Business Overview
11.1.3 Gliead Small Molecule Drug CDMO Services Introduction
11.1.4 Gliead Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.1.5 Gliead Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Small Molecule Drug CDMO Services Introduction
11.2.4 Boehringer Ingelheim Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.2.5 Boehringer Ingelheim Recent Development
11.3 Vertex
11.3.1 Vertex Company Details
11.3.2 Vertex Business Overview
11.3.3 Vertex Small Molecule Drug CDMO Services Introduction
11.3.4 Vertex Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.3.5 Vertex Recent Development
11.4 Mirati Therapeutics
11.4.1 Mirati Therapeutics Company Details
11.4.2 Mirati Therapeutics Business Overview
11.4.3 Mirati Therapeutics Small Molecule Drug CDMO Services Introduction
11.4.4 Mirati Therapeutics Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.4.5 Mirati Therapeutics Recent Development
11.5 AMPAC
11.5.1 AMPAC Company Details
11.5.2 AMPAC Business Overview
11.5.3 AMPAC Small Molecule Drug CDMO Services Introduction
11.5.4 AMPAC Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.5.5 AMPAC Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Small Molecule Drug CDMO Services Introduction
11.6.4 Pfizer Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Polypeptide
11.7.1 Polypeptide Company Details
11.7.2 Polypeptide Business Overview
11.7.3 Polypeptide Small Molecule Drug CDMO Services Introduction
11.7.4 Polypeptide Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.7.5 Polypeptide Recent Development
11.8 Bachem
11.8.1 Bachem Company Details
11.8.2 Bachem Business Overview
11.8.3 Bachem Small Molecule Drug CDMO Services Introduction
11.8.4 Bachem Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.8.5 Bachem Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck Small Molecule Drug CDMO Services Introduction
11.9.4 Merck Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.9.5 Merck Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Details
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Small Molecule Drug CDMO Services Introduction
11.10.4 Asymchem Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.10.5 Asymchem Recent Development
11.11 Thermo Fisher Scientific
11.11.1 Thermo Fisher Scientific Company Details
11.11.2 Thermo Fisher Scientific Business Overview
11.11.3 Thermo Fisher Scientific Small Molecule Drug CDMO Services Introduction
11.11.4 Thermo Fisher Scientific Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.11.5 Thermo Fisher Scientific Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Details
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Small Molecule Drug CDMO Services Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
11.13 Porton Fine Chemicals
11.13.1 Porton Fine Chemicals Company Details
11.13.2 Porton Fine Chemicals Business Overview
11.13.3 Porton Fine Chemicals Small Molecule Drug CDMO Services Introduction
11.13.4 Porton Fine Chemicals Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.13.5 Porton Fine Chemicals Recent Development
11.14 Lonza Group
11.14.1 Lonza Group Company Details
11.14.2 Lonza Group Business Overview
11.14.3 Lonza Group Small Molecule Drug CDMO Services Introduction
11.14.4 Lonza Group Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.14.5 Lonza Group Recent Development
11.15 JOINN Biologics
11.15.1 JOINN Biologics Company Details
11.15.2 JOINN Biologics Business Overview
11.15.3 JOINN Biologics Small Molecule Drug CDMO Services Introduction
11.15.4 JOINN Biologics Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.15.5 JOINN Biologics Recent Development
11.16 Zhejiang Langhua Pharmaceutical
11.16.1 Zhejiang Langhua Pharmaceutical Company Details
11.16.2 Zhejiang Langhua Pharmaceutical Business Overview
11.16.3 Zhejiang Langhua Pharmaceutical Small Molecule Drug CDMO Services Introduction
11.16.4 Zhejiang Langhua Pharmaceutical Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.16.5 Zhejiang Langhua Pharmaceutical Recent Development
11.17 Kingchem (Liaoning) Life Science
11.17.1 Kingchem (Liaoning) Life Science Company Details
11.17.2 Kingchem (Liaoning) Life Science Business Overview
11.17.3 Kingchem (Liaoning) Life Science Small Molecule Drug CDMO Services Introduction
11.17.4 Kingchem (Liaoning) Life Science Revenue in Small Molecule Drug CDMO Services Business (2019-2024)
11.17.5 Kingchem (Liaoning) Life Science Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Thermo Fisher Scientific
Zhejiang Jiuzhou Pharmaceutical
Porton Fine Chemicals
Lonza Group
JOINN Biologics
Zhejiang Langhua Pharmaceutical
Kingchem (Liaoning) Life Science

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.